Market Research Logo

Global Short Bowel Syndrome (SBS) Market 2017-2021

Global Short Bowel Syndrome (SBS) Market 2017-2021

About Short Bowel Syndrome (SBS)

Short bowel syndrome (SBS) is a metabolic disorder occurs when the portion of the small intestine is not functioning or removed through surgery due to digestive illness. SBS is caused by lack of function of the small intestine. This results in malabsorption, diarrhea, steatorrhea, fluid and electrolyte disturbances, and malnutrition. Based on drug class, the market is segmented into GLP-2, growth hormone, glutamine, and others.

Technavio’s analysts forecast the global short bowel syndrome (SBS) market to grow at a CAGR of 25.53% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global short bowel syndrome (SBS) market for 2017-2021. To calculate the market size, the report considers the sales of the drugs and related nutraceutical products.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Short Bowel Syndrome (SBS) Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Emmaus Medical
  • Merck
  • Shire
Other prominent vendors
  • Ardelyx
  • Naia Pharmaceuticals
  • Nutrinia
  • OxThera
  • Sancilio Pharmaceuticals
  • Zealand Pharma
Market driver
  • Special drug designations
  • For a full, detailed list, view our report
Market challenge
  • Severe side effects of the drugs
  • For a full, detailed list, view our report
Market trend
  • Increased awareness of GI disorders
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Short Bowel Syndrome (SBS) Market 2017-2021

Technavio recognizes the following companies as the key players in the global short bowel syndrome (SBS) market: Emmaus Medical, Merck, and Shire.

Other Prominent Vendors in the market are: Ardelyx, Naia Pharmaceuticals, Nutrinia, OxThera, Sancilio Pharmaceuticals, and Zealand Pharma.

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is increased awareness of GI disorders. Pharmaceutical companies and national and local government bodies such as the health ministry and municipalities are conducting programs to spread awareness of GI disorders. Many NGOs also conduct camps to educate people and raise the awareness level. Drug manufacturers supply visual aids or free samples to physicians and sometimes to individuals to spread awareness of the disorders and promote their drugs. This is done to increase the knowledge of the individuals about a particular GI disorder.”

According to the report, one of the major drivers for this market is special drug designations. As the market is dominated by a few drugs and the pipeline also demonstrates the same, the special designation will provide more opportunity for revenue generation and to expand geographically. These designations carry benefits such as an extension of patent exclusivity period to address the need for an orphan drug, tax credits of up to 50% of R&D costs, and orphan drug’s sponsors are exempted from paying the US FDA application fees. These benefits will reduce the burden from vendors to develop a product for a rare disease.

Further, the report states that one of the major factors hindering the growth of this market is severe side effects of the drugs. The side effects involved in the use of GATTEX may hinder the adoption rates. GATTEX is a GLP-2 analog used for the treatment of adult patients with SBS who are dependent on parenteral support. There is an increased risk that abnormal cells could become cancer. The few other side effects associated with GATTEX is swelling (inflammation) or blockage in gallbladder or pancreas or fluid overload. These side effects could lead to trouble in having a bowel movement or passing gas, stomach area (abdomen) pain or swelling, nausea, vomiting, swelling, and blockage in stoma opening.

Emmaus Medical, Merck, Shire, Ardelyx, Naia Pharmaceuticals, Nutrinia, OxThera, Sancilio Pharmaceuticals, and Zealand Pharma.

  • Executive summary
  • Scope of the report
  • Research Methodology
  • Introduction
    • Market outline
      • Table Parts of small intestine
      • Table Causes of SBS
      • Table Key SBS drugs
    • Diagnosis and testing
      • Table Diagnostic test for SBS
  • Orphan drug designation
    • Table Incentives of orphan drug designation
    • Table Orphan drugs approved for SBS
    • Table Overview of case study I
    • Table Overview of case study II
    • Table Overview of case study III
  • Pipeline landscape
    • Table Global SBS market: Pipeline landscape
  • Market landscape
    • Market overview
      • Table Global SBS market overview
      • Table Global SBS market 2016-2021 ($ millions)
      • Table Opportunity analysis in global SBS market
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by route of administration (ROA)
    • Table Segmentation of global SBS market by ROA 2016
    • Table Market share of global SBS market by ROA 2016 (%)
    • Oral
    • Parenteral
  • Market segmentation by drug class
    • Table Segmentation of global SBS market by drug class 2016
    • Table Market share of global SBS market by drug class 2016 (%)
    • GLP-2
      • Table Global GLP-2 drugs market 2016-2021 ($ millions)
    • Growth hormone
      • Table Global SBS human growth hormone market 2016-2021 ($ millions)
    • Glutamine
      • Table Global SBS glutamine market 2016-2021 ($ millions)
    • Others
  • Geographical segmentation
    • Table Segmentation of SBS market based on geography 2016 and 2021
    • Table Global SBS market revenue by geography 2016-2021 ($ millions)
    • SBS market in Americas
      • Table Market scenario in Americas
      • Table SBS market in Americas 2016-2021 ($ millions)
    • SBS in EMEA
      • Table Market scenario of EMEA
      • Table SBS market in EMEA 2016-2021 ($ millions)
    • SBS market in APAC
      • Table Market scenario of APAC
      • Table SBS market in APAC 2016-2021 ($ millions)
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Key approvals for different regions
    • Market challenges
  • Market trends
    • Increased awareness of GI disorders
    • Emerging markets
    • Focus on gene therapy
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global SBS market 2016
      • Table Strategic success factors of companies in global SBS market
  • Key vendor analysis
    • Emmaus Medical
      • Table Emmaus Medical: Strength assessment
      • Table Emmaus Medical: Strategy assessment
      • Table Emmaus Medical: Opportunity assessment
    • Merck
      • Table Merck: Strength assessment
      • Table Merck: Strategy assessment
      • Table Merck: Opportunity assessment
    • Shire
      • Table Shire: Key highlights
      • Table Shire: Strength assessment
      • Table Shire: Strategy assessment
      • Table Shire: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report